Developing Novel Monoclonal Antibody Therapeutics
TrueBinding Inc. is a clinical stage biotherapeutic company creating new and exciting molecules for applications in neurodegenerative and metabolic diseases, stroke, oncology and other areas with great unmet medical need.
Revolutionizing Patient Care
TrueBinding is optimizing patient care through its revolutionary pipeline of monoclonal antibody therapeutics, providing targeted treatments for a diverse range of diseases and medical conditions. By harnessing the power of our platform technology, we rapidly develop and deliver highly specific and effective monoclonal antibodies, ushering in a new era of precision medicine that holds the promise of improved patient outcomes and enhanced therapeutic options.
Accelerating Biopharmaceutical Innovation
TrueBinding's contract development and manufacturing services offer unparalleled benefits for clients in the biopharmaceutical industry. By leveraging our advanced technology and expertise, our teams can accelerate the development process, ensuring rapid and efficient production of high-quality monoclonal antibodies, ultimately enabling clients to bring their innovative therapies to market faster and more cost-effectively.
TB006 Expanded Access Program
Granting access to investigational medications, the Expanded Access Program (EAP) for TB006 offers a compassionate approach to providing potential benefits to patients who have exhausted all other alternatives combating Alzheimer’s Disease.
Completion of Phase 1b/2a Clinical Trial for Alzheimer's Disease
Topline data from a one-month TB006 treatment regimen shows improvements in Clinical Dementia Rating-Sum of Boxes (CDR-SB) in patients, indicating the potential of slowing or reducing clinical decline. Key secondary endpoints were consistent with the primary findings that TB006 improved cognition and function in patients
Latest News
April 21th, 2023
TrueBinding's investigational therapy TB006 has shown promising results in a study involving Alzheimer's disease patients. Nearly half of the patients treated with TB006 for three months or longer showed signs of disease reversal or cognitive improvement.
March 28, 2023
TrueBinding announced early results from an Open-Label Extension (OLE) study of its TB006 drug for Alzheimer's Disease. The study showed potential for disease reversal and sustained clinical benefits beyond the drug's phase 2a trial success, with a significant number of participants experiencing disease stabilization or improvement.
February 28, 2023
The FDA has granted TrueBinding a Type B, end of phase 2a, teleconference face-to-face meeting. This meeting will focus on discussing the rapid development pathway for their drug, TB006, in the treatment of Alzheimer's disease. TrueBinding has completed phase 2a clinical trials and seeks to accelerate the drug's approval process.